Merke Deborah P, Bornstein Stefan R
Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development and the Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1932, USA.
Lancet. 2005;365(9477):2125-36. doi: 10.1016/S0140-6736(05)66736-0.
Congenital adrenal hyperplasia (CAH) due to deficiency of 21-hydroxylase is a disorder of the adrenal cortex characterised by cortisol deficiency, with or without aldosterone deficiency, and androgen excess. Patients with the most severe form also have abnormalities of the adrenal medulla and epinephrine deficiency. The severe classic form occurs in one in 15,000 births worldwide, and the mild non-classic form is a common cause of hyperandrogenism. Neonatal screening for CAH and gene-specific prenatal diagnosis are now possible. Standard hormone replacement fails to achieve normal growth and development for many children with CAH, and adults can experience iatrogenic Cushing's syndrome, hyperandrogenism, infertility, or the development of the metabolic syndrome. This Seminar reviews the epidemiology, genetics, pathophysiology, diagnosis, and management of CAH, and provides an overview of clinical challenges and future therapies.
由于21-羟化酶缺乏所致的先天性肾上腺皮质增生症(CAH)是一种肾上腺皮质疾病,其特征为皮质醇缺乏,伴或不伴有醛固酮缺乏,以及雄激素过多。最严重形式的患者还存在肾上腺髓质异常和肾上腺素缺乏。严重的经典型在全球每15000例出生中出现1例,轻度非经典型是高雄激素血症的常见原因。现在可以对CAH进行新生儿筛查和基因特异性产前诊断。对于许多CAH患儿,标准的激素替代疗法无法实现正常的生长发育,而成人可能会出现医源性库欣综合征、高雄激素血症、不孕或代谢综合征。本研讨会回顾了CAH的流行病学、遗传学、病理生理学、诊断和管理,并概述了临床挑战和未来治疗方法。